Home Cart Sign in  
Chemical Structure| 633328-95-7 Chemical Structure| 633328-95-7

Structure of 633328-95-7

Chemical Structure| 633328-95-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 633328-95-7 ]

CAS No. :633328-95-7
Formula : C5H4BrClN2
M.W : 207.46
SMILES Code : BrC1=CN=C(N=C1C)Cl
MDL No. :MFCD13193654
InChI Key :IIALSLVGUGOODS-UHFFFAOYSA-N
Pubchem ID :20600736

Safety of [ 633328-95-7 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340+P312-P305+P351+P338-P332+P313-P337+P313-P403+P233-P405-P501

Computational Chemistry of [ 633328-95-7 ] Show Less

Physicochemical Properties

Num. heavy atoms 9
Num. arom. heavy atoms 6
Fraction Csp3 0.2
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 39.71
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

25.78 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.09
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.26
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.2
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.33
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.7
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.12

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.04
Solubility 0.188 mg/ml ; 0.000905 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.44
Solubility 0.757 mg/ml ; 0.00365 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.51
Solubility 0.0635 mg/ml ; 0.000306 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.96 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.67

Application In Synthesis of [ 633328-95-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 633328-95-7 ]

[ 633328-95-7 ] Synthesis Path-Downstream   1~4

  • 1
  • [ 290328-57-3 ]
  • [ 633328-95-7 ]
  • 7-fluoro-4-(4-methyl-2-((S)-3-(methylsulfonyl)pyrrolidin-1-yl)pyrimidin-5-yl)-1,4-dihydropyrazolo[4,3-b]indole trifluoroacetate [ No CAS ]
  • 2
  • [ 290328-57-3 ]
  • [ 633328-95-7 ]
  • [ 1578256-82-2 ]
YieldReaction ConditionsOperation in experiment
80% With triethylamine; In ethanol; at 75.0℃; for 72.0h; STEP A: (S)-5-Bromo-4-methyl-2-(3-(methylsulfonyl)pyrrolidin-1-yl)pyrimidine [0638] A 40 mL vial was charged with 5-bromo-2-chloro-4-methylpyrimidine (348 mg, 1.675 mmol), (5)-3-(methylsulfonyl)pyrrolidine (250 mg, 1.675 mmol), and Et3N (0.701 mL, 5.03 mmol) in EtOH (90 mL). The resulting yellow solution was stirred at 75C for 3 days. The reaction mixture was partitioned between water (40 mL) and ethyl acetate (40 mL). The organic and aqueous layers were separated, and the aqueous layer was back-extracted with ethyl acetate (75 mL). The organic layers were combined, washed with brine (40 mL), dried over Na2S04, filtered, and concentrated to give the title compound as a white solid, which was used without further purification (430 mg, 80%).
  • 3
  • [ 17321-93-6 ]
  • [ 633328-95-7 ]
YieldReaction ConditionsOperation in experiment
45% With tert.-butylnitrite; N-benzyl-N,N,N-triethylammonium chloride; In dichloromethane; at 25℃; for 2h; Tert-butyl nitrite (16 g, 155 mmol) was added dropwise to a mixture of <strong>[17321-93-6]5-bromo-4-methyl-2-pyrimidinylamine</strong> (5 g, 26.59 mmol), and benzyltriethylammoniumchloride (27 g, 118.54 mmol) in dichloromethane (200 mL). The reaction mixture was stirred at 25° C. for 2 hours. The reaction mixture was diluted with H2O (50 mL), neutralized with sat. NaHCO3 and extracted with dichloromethane (300 mL×3). All of the dichloromethane layers were combined, dried over Na2SO4, filtered and evaporated. The residue was purified by silica-gel column chromatography (petroleum ether/ethyl acetate=10:1) to give 5-bromo-2-chloro-4-methyl-pyrimidine (2.5 g, 45percent yield) as a white solid. LCMS (ESI) [M+H]+=208.9.
  • 4
  • [ 633328-95-7 ]
  • [ 76350-90-8 ]
  • 5-bromo-4-methyl-2-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)pyrimidine [ No CAS ]
YieldReaction ConditionsOperation in experiment
17% To a stirred solution of (2-methyl-[l,l*-biphenyl]-3-yl)methanol (7.1 g, 0.036 mol) in DMF (60 mL) at 0C, sodium hydride (1.73 g, 60% in minerali oil, 0.043 mol) was added and stirred at room temperature for 30 minutes. To this mixture, 5- bromo-2-chloro-4-methylpyrimidine (5 g, 0.024 mol) was added and allowed to stir at room temperature for 16h. After completion of the reaction, the reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layer was then dried over sodium sulfate, filtered and evaporated to give crude product. The crude product was purified on column chromatography (silicagel, 100-200) using 10% ethyl acetate in hexane as eluent to afford 5-bromo-4- methyl-2-((2-methyl-[l, -biphenyl]-3-yl)methoxy)pyrimidine as off-white solid (Yield: 1.5 g, 17%). LCMS (ES) m/z = 369.01 [M+H]+; MR (400 MHz, CDC13): delta 2.31 (s, 3H), 2.58 (s, 3H), 5.47 (s, 2H), 7.21-7.23 (m, 2H), 7.25-7.30 (m, 2H), 7.35 (m, 1H), 7.39-7.43 (m, 2H), 7.49 (m, 1H), 8.47 (s, 1H). HPLC purity 214 nm, 99.78%.
 

Historical Records

Technical Information

Categories

Similar Product of
[ 633328-95-7 ]

Chemical Structure| 1622843-62-2

A1627868 [1622843-62-2]

5-Bromo-2-chloro-4-cyclopropylpyrimidine

Reason: Derivatives

Chemical Structure| 32779-36-5

A107210 [32779-36-5]

5-Bromo-2-chloropyrimidine

Reason: Derivatives

Related Functional Groups of
[ 633328-95-7 ]

Bromides

Chemical Structure| 32779-36-5

A107210 [32779-36-5]

5-Bromo-2-chloropyrimidine

Similarity: 0.85

Chemical Structure| 4786-72-5

A122390 [4786-72-5]

5-Bromo-2-chloro-4,6-dimethylpyrimidine

Similarity: 0.81

Chemical Structure| 1439-09-4

A189946 [1439-09-4]

5-Bromo-4-methylpyrimidine

Similarity: 0.81

Chemical Structure| 951884-36-9

A158021 [951884-36-9]

5-Bromo-4-ethylpyrimidine

Similarity: 0.78

Chemical Structure| 1439-08-3

A162355 [1439-08-3]

5-Bromo-4-(tert-butyl)pyrimidine

Similarity: 0.73

Chlorides

Chemical Structure| 32779-36-5

A107210 [32779-36-5]

5-Bromo-2-chloropyrimidine

Similarity: 0.85

Chemical Structure| 4786-72-5

A122390 [4786-72-5]

5-Bromo-2-chloro-4,6-dimethylpyrimidine

Similarity: 0.81

Chemical Structure| 13036-57-2

A231936 [13036-57-2]

2-Chloro-4-methylpyrimidine

Similarity: 0.77

Chemical Structure| 75833-38-4

A182805 [75833-38-4]

2-Chloropyrimidine-4-carbonitrile

Similarity: 0.72

Chemical Structure| 36082-50-5

A506344 [36082-50-5]

5-Bromo-2,4-dichloropyrimidine

Similarity: 0.70

Related Parent Nucleus of
[ 633328-95-7 ]

Pyrimidines

Chemical Structure| 32779-36-5

A107210 [32779-36-5]

5-Bromo-2-chloropyrimidine

Similarity: 0.85

Chemical Structure| 4786-72-5

A122390 [4786-72-5]

5-Bromo-2-chloro-4,6-dimethylpyrimidine

Similarity: 0.81

Chemical Structure| 1439-09-4

A189946 [1439-09-4]

5-Bromo-4-methylpyrimidine

Similarity: 0.81

Chemical Structure| 951884-36-9

A158021 [951884-36-9]

5-Bromo-4-ethylpyrimidine

Similarity: 0.78

Chemical Structure| 13036-57-2

A231936 [13036-57-2]

2-Chloro-4-methylpyrimidine

Similarity: 0.77